140 related articles for article (PubMed ID: 32002804)
1. The role of TP53 gain-of-function mutation in multifocal glioblastoma.
Olafson LR; Gunawardena M; Nixdorf S; McDonald KL; Rapkins RW
J Neurooncol; 2020 Mar; 147(1):37-47. PubMed ID: 32002804
[TBL] [Abstract][Full Text] [Related]
2. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
3. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
4. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
5. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
6. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
7. TP53 deleted cells in de novo glioblastomas using fluorescence in situ hybridization.
Horiguchi H; Sano T; Hirose T
Pathol Int; 2001 Mar; 51(3):187-92. PubMed ID: 11328534
[TBL] [Abstract][Full Text] [Related]
8. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
Burton EC; Lamborn KR; Forsyth P; Scott J; O'Campo J; Uyehara-Lock J; Prados M; Berger M; Passe S; Uhm J; O'Neill BP; Jenkins RB; Aldape KD
Clin Cancer Res; 2002 Jan; 8(1):180-7. PubMed ID: 11801556
[TBL] [Abstract][Full Text] [Related]
9. A new method of identifying glioblastoma subtypes and creation of corresponding animal models.
Zhou X; Li G; An S; Li WX; Yang H; Guo Y; Dai Z; Dai S; Zheng J; Huang J; Iavarone A; Zhao X
Oncogene; 2018 Aug; 37(35):4781-4791. PubMed ID: 29769617
[TBL] [Abstract][Full Text] [Related]
10. Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy.
Tang C; Guo J; Chen H; Yao CJ; Zhuang DX; Wang Y; Tang WJ; Ren G; Yao Y; Wu JS; Mao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(5):5327-35. PubMed ID: 26191234
[TBL] [Abstract][Full Text] [Related]
11. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines.
Godoy PR; Mello SS; Magalhães DA; Donaires FS; Nicolucci P; Donadi EA; Passos GA; Sakamoto-Hojo ET
Mutat Res; 2013 Aug; 756(1-2):46-55. PubMed ID: 23817105
[TBL] [Abstract][Full Text] [Related]
12. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
Sande CM; Chang B; Monga V; Bossler AD; Ma D
Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a new glioblastoma cell line, GB-val4, with unusual TP53 mutation.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Gil-Benso R; Cerdá-Nicolás M; López-Ginés C
Hum Cell; 2019 Oct; 32(4):557-567. PubMed ID: 31388924
[TBL] [Abstract][Full Text] [Related]
14. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.
Cho SY; Park C; Na D; Han JY; Lee J; Park OK; Zhang C; Sung CO; Moon HE; Kim Y; Kim JH; Kim JJ; Khang SK; Nam DH; Choi JW; Suh YL; Kim DG; Park SH; Youn H; Yun K; Kim JI; Lee C; Paek SH; Park H
Exp Mol Med; 2017 Apr; 49(4):e317. PubMed ID: 28408749
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
Abou-El-Ardat K; Seifert M; Becker K; Eisenreich S; Lehmann M; Hackmann K; Rump A; Meijer G; Carvalho B; Temme A; Schackert G; Schröck E; Krex D; Klink B
Neuro Oncol; 2017 Apr; 19(4):546-557. PubMed ID: 28201779
[TBL] [Abstract][Full Text] [Related]
18. Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Case report.
Hayashi Y; Iwato M; Hasegawa M; Tachibana O; von Deimling A; Yamashita J
J Neurosurg; 2001 Jul; 95(1):138-42. PubMed ID: 11453385
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
